When a difficult-to-enroll Phase 3 study stalled, Keenova found momentum not through new technology but through relationships, collaboration, and fair site support. By listening to site feedback, rethinking communication, empowering peer learning, and revisiting compensation, the team transformed engagement and enrollment.
- When A Clinical Trial Surfaces In An AI Chat, What Happens Next?
- Outsourcing? When Both Sides Of The Table Are Investor-Backed, Everything Changes
- Pick The Right PV Technology With Help From A Safety Data Management Expert
- Tekton's CEO On The Growing Power Of Site Networks
- The Cost Of Transactional Thinking In Clinical Research
- Say It Loud: Clinical Research Needs New Voices
- Site-Centric First, Patient-Centric Always
GUEST COLUMNISTS
-
![Hospital management meeting-GettyImages-1134045124]( "Why Sponsors Should Share KPI Rationale With Sites")
Why Sponsors Should Share KPI Rationale With SitesTo build partnerships, foster transparency, and promote shared accountability, Curo Research CEO Amy Bland explains why sponsors need to communicate the utility of KPIs with sites.
-
![Parkinson's symptoms-GettyImages-1688988054]( "Rethinking Clinical Trials In Rare Neurodegenerative Diseases: Lessons From Alterity's MSA Trial")
Rethinking Clinical Trials In Rare Neurodegenerative Diseases: Lessons From Alterity's MSA TrialAlterity Therapeutics CEO David Stamler shares how early diagnosis, biomarker-guided design, and precise patient selection positively impacted a trial in multiple system atrophy (MSA).
-
![GettyImages-1602744313 assay]( "Breaking Through Tumor Defenses With Next-Generation Cell Therapy")
Breaking Through Tumor Defenses With Next-Generation Cell TherapyErnexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.
-
![Tumor Cancer Cells-GettyImages-2203606213]( "Reprogramming The Tumor Microenvironment: Bringing A Metabolic Checkpoint Therapy Into The Clinic")
Reprogramming The Tumor Microenvironment: Bringing A Metabolic Checkpoint Therapy Into The ClinicPilatus Biosciences CEO Raven Lin shares learnings from his company's early-stage oncology program.
-
![Father playing with child-GettyImages-1567083882]( "Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease")
Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare DiseaseThe inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
The Problem With Excluding Children From GLP-1 Trials In The U.S.In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Various Pills on White Stripes of American Flag-GettyImages-172849908]( "U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact")
U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement ImpactBeroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial WorkflowsLearn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
CLINICAL TRIAL WHITE PAPERS
-
![Medical data risk iStock-1185375169]( "Modernizing Clinical Trial Oversight: The Path To Clinical Operations Excellence")
Modernizing Clinical Trial Oversight: The Path To Clinical Operations ExcellenceExamine the current state of RBQM approaches to virtualizing clinical oversight, and the value that adopting these approaches brings to sponsors, CROs, sites, and ultimately patients.
-
2025 Safety And Regulatory Compliance Trends And Predictions12/16/2024
Explore the rapidly evolving regulatory landscape that pharmaceutical and biotech industries face as they integrate AI and advanced technologies into safety, compliance, and lifecycle management.
-
eCOA Licensing Guide3/7/2024
In this comprehensive guide, IQVIA's eCOA library and licensing specialists, Kayla Doyle and Piero Bindi, explore five essential steps for obtaining licenses for the assessments required in your clinical trial.
-
Endpoint Clinical RTSM: Getting The Job Done12/5/2025
Explore how a Job-to-be-Done (JTBD)-focused RTSM approach reduces delays, optimizes costs, and accelerates trial success through predictive intelligence and streamlined global workflows.
-
Digital Endpoint Resource Guide: Parkinson's Disease8/20/2024
Explore how sensor-based digital health technologies can revolutionize the treatment and management of movement disorders by providing more accurate, patient-centered outcomes.
-
A New Blueprint For Transforming Feasibility And Recruitment9/22/2025
Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
GSK And Medable Discuss The Next Phase Of DCTs3/10/2025
GSK and Medable share the value of embedding DCTs into strategic goals to enhance trial accessibility, diversity, and efficiency.
-
Analytics–Powered Approach To Patient Recruitment Strategy7/15/2025
In a Phase 3 psychiatry trial, a pharmaceutical company partnered with Signant to revolutionize patient recruitment through data-driven site selection using PureSignal Analytics.
-
Data Key In Addressing Patient Recruitment Challenges6/19/2025
Explore how a Phase II trial for extensive-stage and previously treated small cell lung cancer overcame recruitment challenges with a data-driven solution designed to surface protocol-matched patients.
-
Enhancing Phase 1 Clinical Trials With Point-Of-Need Safety Assessments2/3/2025
A Mobile Clinical Suite (MCS) proved to be the solution that Syneos Health needed to resolve their Phase 1 study trial challenges with comprehensive eye exams.
-
Biotech Delivers A Superior Patient And Site Experience3/4/2025
To become the sponsor of choice for sites and patients in congenital hyperinsulinism clinical trials, a small biotech company prioritized delivering a superior experience while streamlining operations.
-
Use Case: A Patient-Centric Approach To Site Selection1/27/2025
Discover how Citeline’s robust datasets, combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease.
NEWSLETTER ARCHIVE
- 03.03.26 -- How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows
- 03.02.26 -- Sites Are Driving Clinical Tech Evolution
- 02.27.26 -- Site Management And Oversight Become Must-Haves For Successful Sites
- 02.27.26 -- Overcoming Enrollment And Site Challenges
- 02.26.26 -- Why Dr. Robert Califf Isn't Pulling His Punches Anymore
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![Chat bot service, future marketing-GettyImages-1468141962]( "When A Clinical Trial Surfaces In An AI Chat, What Happens Next?")
AI is soon becoming the first interpreter of your clinical trial. Understand its implications for enrollment design, screening efficiency, and ultimately program predictability.
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
FOCUS ON PATIENTS
-
![Father playing with child-GettyImages-1567083882]( "Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease")
The inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
